Poolbeg Pharma (LON:POLB) Receives House Stock Rating from Shore Capital Group

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating reaffirmed by research analysts at Shore Capital Group in a report issued on Tuesday,Digital Look reports.

Poolbeg Pharma Price Performance

Shares of POLB stock opened at GBX 5.56 on Tuesday. The stock has a market capitalization of £39.17 million, a PE ratio of -5.91 and a beta of 1.78. Poolbeg Pharma has a 1-year low of GBX 2.40 and a 1-year high of GBX 5.80. The business has a 50-day moving average of GBX 4.44 and a 200 day moving average of GBX 4.28.

Poolbeg Pharma (LON:POLB) last issued its earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. Analysts anticipate that Poolbeg Pharma will post -0.68 EPS for the current year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.